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In 2015, the World Health Organization (WHO) launched 
the End TB strategy, which has three pillars—integrated, 
patient-centered care and prevention; bold policies 
and supportive systems; and intensified research and 
innovation—and has the inbuilt concept of the elimination 
of tuberculosis.(1-4) The elimination of tuberculosis has 
been defined as < 1 case per million population, pre-
elimination having been defined as < 10 cases per million. 
Since then, the three pillars have been officially adopted 
by a number of countries(5): in 2015, by Brazil, Ethiopia, 
the Russian Federation, South Africa, and Vietnam; and 
in 2016, by India, Indonesia, Swaziland, and Thailand.
Following a joint WHO/European Respiratory Society 
(ERS) consultation with countries with a low incidence of 
tuberculosis (< 10 cases per 100,000 population), held in 
Rome in 2014, the WHO launched its Framework Towards 
Tuberculosis Elimination In Low-Incidence Countries.(1) 
The document identified eight major areas to be tackled 
in order to eliminate tuberculosis in such countries.(1)
In epidemiological terms, tuberculosis control strategies 
focus on the early identification and effective treatment 
of cases of infectious tuberculosis (to break the chain 
of transmission and reduce the incidence); tuberculosis 
elimination is an additional strategy which has at its 
core the identification of latently infected individuals and 
their treatment (to sterilize the “reservoir” of infected 
persons and ensure future generations of infection-free 
individuals),(1,6,7) investing today to prevent tuberculosis 
cases tomorrow.(1,6,7) There is evidence that, when applied 
consistently, the tuberculosis elimination strategy has 
been effective. For example, it has been reported to have 
reduced the incidence of tuberculosis by up to 17% per 
year in Inuit populations.(8)
An initial question to be answered is whether there have 
been any reports of experiences with the tuberculosis 
elimination strategy in high-burden countries. Recent 
studies conducted in the countries of Cyprus and Oman 
have shown that the appropriate implementation of the 
basic elements of the End TB strategy can drive the 
epidemiology of tuberculosis toward the pre-elimination 
threshold.(9,10) A second question is to what extent the 
tuberculosis elimination strategy can be applied in Latin 
America and the Caribbean, where there are a number of 
low-incidence countries—including the Bahamas, Chile, 
Costa Rica, Cuba, the Dominican Republic, Jamaica, and 
Puerto Rico, as well as Trinidad and Tobago—and others 
that are approaching that threshold—including Brazil, 
Uruguay, and Colombia—those in the latter category 
also having been invited to the WHO/ERS technical 
consultation in Rome in 2014.
In parallel with the publication of the WHO framework,(1) 
the Pan American Health Organization (PAHO) created 
two important documents. In 2015, the organization 
issued a document including all three pillars of the 
End TB strategy, the PAHO Strategic Plan,(11) which 
followed its Action Plan for the Prevention and Control 
of Tuberculosis. Launched in 2013, the PAHO action plan 
focused on tuberculosis control only, using epidemiological 
indicators (i.e., increased numbers of patients with 
bacteriologically confirmed tuberculosis that was treated 
successfully), promoting cross-cutting approaches in 
health, and covering comorbidities (e.g., HIV infection 
and mental health disorders).(12) Those documents were 
followed by the Roadmap for Tuberculosis Elimination 
in Latin America and the Caribbean, created jointly by 
the ERS and the Asociación Latinoamericana del Tórax 
(ALAT, Latin-American Thoracic Society), to guide national 
tuberculosis programs toward implementation of the 
PAHO strategies. It is clear that there is considerable 
heterogeneity in Latin America in terms of epidemiological 
actions and programs, the strategic goals mentioned above 
therefore being met at different paces.(3,4) One example 
is provided by the epidemiology of tuberculosis in Mexico 
(Figure 1), where the reported incidence of the disease 
is below the low-incidence threshold in one third of the 
states, < 20 per 100,000 population in another third, 
and higher than that in the remaining third.
In 2017, the Brazilian National Ministry of Health issued 
a document aimed at the elimination of tuberculosis, 
the National Plan to End Tuberculosis as a Public Health 
Problem. The plan was designed with the goal of reducing 
tuberculosis incidence (to < 10 cases/100,000 population) 
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and mortality (to < 1 death/100,000 population) by 
2035, defining the approaches to implementing each 
of the three pillars of the WHO End TB strategy.(13)
In Latin America, visible progress has been made 
toward meeting the goals set for tuberculosis 
incidence, prevalence, and mortality.(3,4) Among the 
remarkable successes achieved are increased detection 
rates, improved laboratory quality assurance, better 
systematic management of cases of multidrug-resistant 
tuberculosis (MDR-TB), and the promotion of community 
involvement, as well as coordination of technical and 
financial partners.(3,4)
Although there has been a decrease in the reported 
number of new cases in Brazil, that decrease has been 
modest (only 1.5% per year) and more needs to be 
done to improve treatment outcomes, reduce losses 
to follow-up, and prevent the emergence of MDR-TB.
(14) Clearly, there is a need for political commitment 
(with adequate funding and legal framework), true 
patient-centered care, and attention to comorbidities, 
as well as the control of risk factors such as diabetes, 
HIV infection, illicit drug use, smoking, and mental 
disorders.(15) Special attention should also be given 
to vulnerable groups (e.g., migrants from rural areas 
to large cities, south-south migrants (i.e., migrants 
between developing countries), people living in 
slums, underserved indigenous populations, homeless 
individuals, and prisoners).(16)
The eight core areas identified in the ERS/ALAT 
Roadmap for Tuberculosis Elimination in Latin America 
and the Caribbean provide a clear guide to reaching 
the tuberculosis elimination targets in the region:
1. identifying and supporting vulnerable populations
2. addressing migration and transborder issues
3. strengthening operational research, channeling 
it through agreed-upon national research plans 
prioritized by national tuberculosis research 
networks and adequately funded to tackle the 
intensified research/innovation pillar of the End 
TB strategy
4. fostering political commitment for tuberculosis 
care and prevention in order to implement 
elements of the bold policies/supportive systems 
pillar of the End TB strategy
5. adapting the strategy at the national and regional 
level while promoting global collaboration
6. enhancing active detection and treatment of 
latent tuberculosis infection, as well as active 
tuberculosis, according to the principles of 
tuberculosis elimination(5,17)
7. ensuring early, high-quality treatment of cases 
of drug-resistant tuberculosis and MDR-TB while 
ensuring universal drug-susceptibility testing with 
conventional and/or new molecular methods and 
availability of the necessary second-line drugs 
(in order to tackle, with core area 1, the actions 
included in the integrated, patient-centered care/
prevention pillar of the End TB strategy 
8. improving continuous surveillance, monitoring, 
and evaluating activities to assess the progress 
toward the planned targets and the elimination 
of tuberculosis
Indicators for the monitoring and evaluation of each 
of those components were also proposed (Table 1).(3,4)
The contribution of tuberculosis research networks, 
as proposed by the WHO in 2015, is key to working in 
accordance with regional priorities.(18) The joint ERS/
ALAT/Brazilian Thoracic Society tuberculosis project 
and the Brazilian Tuberculosis Research Network are 
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Figure 1. Incidence of reported cases of pulmonary tuberculosis and associated mortality in Mexico (per 100,000 
population in 2016 and 2015, respectively), by state. Obtained from the Mexican Ministry of Health.
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making significant contributions by generating the 
evidence necessary for successful implementation of 
the tuberculosis elimination strategy.(19) Some of the 
preliminary results are quite encouraging,(20-35) showing 
how important it is to implement all three pillars of 
the WHO End TB strategy in Latin America.
Table 1. Indicators of the impact and implementation of the World Health Organization End TB strategy for Latin-
American and Caribbean countries.
Impact indicators Milestones Targets
2020 2025 2030a 2035b
Reduction in number of TB deaths compared with 2015 35% 75% 90% 95%
Reduction in TB incidence rate compared with 2015 20% 50% 80% 90%
Families facing catastrophic costs due to TB 0% 0% 0% 0%
Implementation indicators Recommended target level
TB treatment coverage ≥ 90%
TB treatment success rate ≥ 90%
Households that experience catastrophic costs due to TB 0%
Newly reported TB cases diagnosed using WHO recommended rapid tests ≥ 90%
Latent TB infection treatment coverage ≥ 90%
Contact investigation coverage ≥ 90%
Drug susceptibility coverage for TB patients 100%
Treatment coverage, new TB drugs ≥ 90%
Documentation of HIV status among TB patients ≥ 90%
Case fatality ratio ≤ 5%
Availability of the planned budget for TB 100%
Implementation of planned monitoring and evaluation activities 100%
TB: tuberculosis; and WHO: World Health Organization. aSustainable development goals. bWorld Health Organization 
End TB strategy targets.
REFERENCES
1. Lönnroth K, Migliori GB, Abubakar I, D’Ambrosio L, de Vries G, Diel 
R, et al. Towards tuberculosis elimination: an action framework for 
low-incidence countries. Eur Respir J. 2015;45(4):928-52. https://doi.
org/10.1183/09031936.00214014
2. D’Ambrosio L, Dara M, Tadolini M, Centis R, Sotgiu G, van der 
Werf MJ, et al. Tuberculosis elimination: theory and practice 
in Europe. Eur Respir J. 2014;43(5):1410-20. https://doi.
org/10.1183/09031936.00198813
3. Rendon A, Fuentes Z, Torres-Duque CA, Granado MD, Victoria 
J, Duarte R, et al. Roadmap for tuberculosis elimination in Latin 
American and Caribbean countries: a strategic alliance. Eur Respir 
J. 2016;48(5):1282-1287. https://doi.org/10.1183/13993003.01549-
2016
4. Torres-Duque CA, Fuentes Alcalá ZM, Rendón A, Migliori GB. 
Roadmap for Tuberculosis Elimination in Latin America and 
the Caribbean. Arch Bronconeumol. 2018;54(1):7-9. https://doi.
org/10.1016/j.arbres.2017.07.004
5. World Health Organization [homepage on the Internet]. Geneva: 
World Health Organization; c2017 [cited 2017 Nov 27]. Global 
tuberculosis report 2017; [about 2 screens]. Available from: http://
www.who.int/tb/publications/global_report/en/
6. de Vries G, van Hest R, Bakker M, Erkens C, van den Hof S, 
Meijer W, et al. Policy and practice of programmatic management 
of latent tuberculosis infection in The Netherlands. J Clin Tuberc 
Other Mycobact Dis. 2017;7:40-48. https://doi.org/10.1016/j.
jctube.2017.02.002
7. Veen J, Migliori GB, Raviglione MC, Rieder HL, Dara M, Falzon D, et 
al. Harmonization of TB control in the WHO European Region: the 
history of the Wolfheze Workshops. Eur Respir J. 2011;37(4):950-9. 
https://doi.org/10.1183/09031936.00019410
8. Grzybowski S, Styblo K, Dorken E. Tuberculosis in Eskimos. 
Tubercle. 1976;57(4 Suppl):S1-58. https://doi.org/10.1016/0041-
3879(76)90059-3
9. Voniatis C, Migliori GB, Voniatis M, Georgiou A, D’Ambrosio 
L, Centis R, et al. Tuberculosis elimination: dream or reality? 
The case of Cyprus. Eur Respir J. 2014;44(2):543-6. https://doi.
org/10.1183/09031936.00044314
10. Al Yaquobi F, Al-Abri S, Al-Abri B, Al-Abaidani I, Al-Jardani A, 
D’Ambrosio L, et al. TB elimination, dream or reality? The case 
of Oman. Eur Respir J. 2018;51(1). pii: 1702027. https://doi.
org/10.1183/13993003.02027-2017
11. Pan American Health Organization [homepage on the Internet]. 
Washington (DC): the Organization; [cited 2017 Nov 27]. Plan of 
Action for the Prevention and Control of Tuberculosis. [Adobe 
Acrobat document, 24p.]. Available from: http://www.paho.org/hq/
index.php?option=com_docman&task=doc_view&gid=31254&Item
id=270&lang=en
12. Pan American Health Organization [homepage on the Internet]. 
Washington (DC): the Organization; [cited 2014 Nov 20]. Strategic 
Plan of the Pan American Health Organization 2014-2019. [Adobe 
Acrobat document, 147p.]. Available from: http://www.paho.org/hq/
index.php?gid=14004&option=com_docman&task=doc_view
13. Brasil. Ministério da Saúde [homepage on the Internet]. Brasília: 
Ministério; c2017 [cited 2017 Nov 27]. Brasil livre da tuberculose 
-- Plano nacional pelo fim da tuberculose como problema de saúde 
pública. 1st edition. [Adobe Acrobat document, 40p.]. Available from: 
http://portalarquivos.saude.gov.br/images/pdf/2017/fevereiro/24/
Plano-Nacional-Tuberculose.pdf
14. Rabahi MF, Silva Júnior JLRD, Conde MB. Evaluation of the 
impact that the changes in tuberculosis treatment implemented 
in Brazil in 2009 have had on disease control in the country. J 
Bras Pneumol. 2017;43(6):437-444. https://doi.org/10.1590/s1806-
37562017000000004
15. Migliori GB, Lienhardt C, Weyer K, van der Werf MJ, Blasi F, Raviglione 
MC. Ensuring rational introduction and responsible use of new TB 
tools. Outcome of an ERS multisector consultation. Eur Respir J. 
2014;44(6):1412-7. https://doi.org/10.1183/09031936.00132114
16. Pareek M, Greenaway C, Noori T, Munoz J, Zenner D. The impact of 
migration on tuberculosis epidemiology and control in high-income 
countries: a review. BMC Med. 2016;14:48. https://doi.org/10.1186/
s12916-016-0595-5
17. Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, 
et al. Management of latent Mycobacterium tuberculosis infection: 
WHO guidelines for low tuberculosis burden countries. Eur Respir J. 
2015;46(6):1563-76. https://doi.org/10.1183/13993003.01245-2015
18. World Health Organization [homepage on the Internet]. Geneva: 
75J Bras Pneumol. 2018;44(2):73-76
Eliminating tuberculosis in Latin America: making it the point
World Health Organization; c2015 [cited 2017 Nov 24]. A global 
action framework for TB research in support of the third pillar of 
WHO’s end TB strategy; [about 2 screens]. Available from: http://
www.who.int/tb/publications/global-framework-research/en/
19. Kritski A, Barreira D, Junqueira-Kipnis AP, Moraes MO, Campos MM, 
Degrave WM, et al. Brazilian Response to Global End TB Strategy: 
The National Tuberculosis Research Agenda. Rev Soc Bras Med 
Trop. 2016;49(1):135-45. https://doi.org/10.1590/0037-8682-0330-
2015
20. Arbex MA, Siqueira HR, D’Ambrosio L, Migliori GB. The challenge 
of managing extensively drug-resistant tuberculosis at a referral 
hospital in the state of São Paulo, Brazil: a report of three cases. 
J Bras Pneumol. 2015;41(6):554-9. https://doi.org/10.1590/s1806-
37562015000000299
21. Dalcolmo M, Gayoso R, Sotgiu G, D’Ambrosio L, Rocha JL, Borga 
L, et al. Effectiveness and safety of clofazimine in multidrug-
resistant tuberculosis: a nationwide report from Brazil. Eur Respir J. 
2017;49(3). pii: 1602445. https://doi.org/10.1183/13993003.02445-
2016
22. Silva DR, Sotgiu G, D’Ambrosio L, Pereira GR, Barbosa MS, Dias NJD, 
et al. Diagnostic performances of the Xpert MTB/RIF in Brazil. Resp 
Med. 2018;134:12-15. https://doi.org/10.1016/j.rmed.2017.11.012
23. Amicosante M, D’Ambrosio L, Munoz MA, Mello FCQ, Tebruegge 
M, Chegou NN, et al. Current use and acceptability of novel 
diagnostic tests for active tuberculosis: a worldwide survey. J Bras 
Pneumol. 2017 Sep-Oct;43(5):380-392. https://doi.org/10.1590/
s1806-37562017000000219
24. Rendon A, Centis R, D’Ambrosio L, Migliori GB. WHO strategies for 
the management of drug-resistant tuberculosis. Arch Bronconeumol. 
2017;53(3):95-97. https://doi.org/10.1016/j.arbres.2016.07.015
25. Muñoz-Torrico M, Caminero-Luna J, Migliori GB, D’Ambrosio L, 
Carrillo-Alduenda JL, Villareal-Velarde H, et al. Diabetes is Associated 
with Severe Adverse Events in Multidrug-Resistant Tuberculosis. 
Arch Bronconeumol. 2017;53(5):245-250. https://doi.org/10.1016/j.
arbr.2016.10.003
26. Muñoz-Torrico M, Caminero Luna J, Migliori GB, D’Ambrosio 
L, Carrillo-Alduenda JL, Villareal-Velarde H, et al. Comparison of 
bacteriological conversion and treatment outcomes among MDR-TB 
patients with and without diabetes in Mexico: Preliminary data. Rev 
Port Pneumol (2006). 2017;23(1):27-30.
27. Bastos ML, Cosme LM, Fregona G, Prado TN, Bertolde AI, 
Zandonade E, et al. Treatment outcomes of MDR-tuberculosis 
patients in Brazil: a retrospective cohort analysis. BMC Infect Dis. 
2017;17(1):718. https://doi.org/10.1186/s12879-017-2810-1
28. Ramalho DMP, Miranda PFC, Andrade MK, Brígido T, Dalcolmo MP, 
Mesquita E, et al. Outcomes from patients with presumed drug 
resistant tuberculosis in five reference centers in Brazil. BMC Infect 
Dis. 2017;17(1):571. https://doi.org/10.1186/s12879-017-2669-1
29. Calderón RI, Velásquez GE, Becerra MC, Zhang Z, Contreras CC, 
Yataco RM, et al. Prevalence of pyrazinamide resistance and Wayne 
assay performance analysis in a tuberculosis cohort in Lima, Peru. 
Int J Tuberc Lung Dis. 2017;21(8):894-901. https://doi.org/10.5588/
ijtld.16.0850
30. Evora LHRA, Seixas JM, Kritski AL. Neural network models for 
supporting drug and multidrug resistant tuberculosis screening 
diagnosis. Neurocomputing. 2017;265:116-126. https://doi.
org/10.1016/j.neucom.2016.08.151
31. Sweetland AC, Kritski A, Oquendo MA, Sublette ME, Norcini Pala A, 
Silva LRB, et al. Addressing the tuberculosis-depression syndemic to 
end the tuberculosis epidemic. Int J Tuberc Lung Dis. 2017;21(8):852-
861. https://doi.org/10.5588/ijtld.16.0584
32. David SG, Lovero KL, Pombo March MFB, Abreu TG, Ruffino Netto 
A, Kritski AL, et al. A comparison of tuberculosis diagnostic systems 
in a retrospective cohort of HIV-infected children in Rio de Janeiro, 
Brazil, Int J Infect Dis. 2017;59:150-155. https://doi.org/10.1016/j.
ijid.2017.01.038
33. de Almeida IN, de Assis Figueredo LJ, Soares VM, Vater MC, Alves 
S, da Silva Carvalho W, et al. Evaluation of the Mean Cost and 
Activity Based Cost in the Diagnosis of Pulmonary Tuberculosis in 
the Laboratory Routine of a High-Complexity Hospital in Brazil. Front 
Microbiol. 2017;8:249. https://doi.org/10.3389/fmicb.2017.00249
34. Wysocki AD, Villa TC, Arakawa T, Brunello ME, Vendramini SH, 
Monroe AA, et al. Latent Tuberculosis Infection Diagnostic and 
Treatment Cascade among Contacts in Primary Health Care in a 
City of Sao Paulo State, Brazil: Cross-Sectional Study. PLoS One. 
2016;11(6):e0155348. https://doi.org/10.1371/journal.pone.0155348
35. Langley, I, Squire SB, Dacombe R, Madan J, Lapa e Silva, JR, Galiez, 
R, et al. Developments in Impact Assessment of New Diagnostic 
Algorithms for Tuberculosis Control. Clin Infect Dis. 2015;61 Suppl 
3:S126-34. https://doi.org/10.1093/cid/civ580
76 J Bras Pneumol. 2018;44(2):73-76
